USPTO Art Unit 1643 Prosecution Statistics

Art Unit Information

Art Unit: 1643
Group: 1640
Tech Center: 1600
Total Cases: 11,241
Last Active: September 2025

Recent Applications

Detailed information about the 100 most recent patent applications.

Application NumberTitleFiling DateDisposal DateDispositionTime (months)Office ActionsRestrictionsInterviewAppeal
19316633IL13 AND IL31 BISPECIFIC POLYPEPTIDES AND USES THEREOFSeptember 2025December 2025Allow300NoNo
19297899BISPECIFIC AGONISTIC ANTIBODIES TO ACTIVIN A RECEPTOR LIKE TYPE 1 (ALK1)August 2025February 2026Allow700YesNo
19293506MUSCLE TARGETING COMPLEXES AND USES THEREOF FOR TREATING DYSTROPHINOPATHIESAugust 2025January 2026Allow500YesNo
19284312ANTIGEN-BINDING PROTEINS AND RELATED METHODS OF USEJuly 2025February 2026Allow710YesNo
19281468METHODS FOR TREATING DIABETIC KIDNEY DISEASE AND GLOMERULAR DISEASEJuly 2025February 2026Allow710NoNo
19259995KLRB1 BINDING AGENTS AND METHODS OF USE THEREOFJuly 2025March 2026Allow810YesNo
19242725COMPOSITIONS AND METHODS FOR TREATMENT OF THYROID EYE DISEASEJune 2025February 2026Allow810YesNo
19229907BISPECIFIC ANTIBODY AND USE THEREOFJune 2025January 2026Allow720NoNo
19217172Method of Use for Benzofuran CompoundsMay 2025February 2026Allow811NoNo
19217020ANTI-TREM2 ANTIBODIES AND METHODS OF USEMay 2025August 2025Allow201YesNo
19205170NOVEL CYTOKINE-BASED THERAPIES AND METHODSMay 2025February 2026Allow1011NoNo
19198507ANTIBODIES THAT BIND TNFRSF25May 2025July 2025Allow200YesNo
19193079BISPECIFIC AGONISTIC ANTIBODIES TO ACTIVIN A RECEPTOR LIKE TYPE 1 (ALK1)April 2025August 2025Allow301YesNo
19188549MUSCLE TARGETING COMPLEXES AND USES THEREOF FOR TREATING DYSTROPHINOPATHIESApril 2025July 2025Allow310NoNo
19182382METHODS OF TREATING GASTROINTESTINAL INFLAMMATORY DISEASEApril 2025July 2025Allow310NoNo
19172374ANTIGEN BINDING POLYPEPTIDESApril 2025July 2025Allow400YesNo
19093136BISPECIFIC ANTI-HUMAN A-BETA/ANTI-HUMAN TRANSFERRIN RECEPTOR ANTIBODIESMarch 2025June 2025Allow211NoNo
19081458PROTEASE-CLEAVABLE SUBSTRATES AND METHODS OF USE THEREOFMarch 2025October 2025Allow710NoNo
19053626ANTI-PTK7 ANTIBODY AND USES THEREOFFebruary 2025October 2025Allow810NoNo
19036915ANTIBODIES THAT BIND TNFRSF25January 2025April 2025Allow300YesNo
19032782MUSCLE TARGETING COMPLEXES AND USES THEREOF FOR TREATING DYSTROPHINOPATHIESJanuary 2025April 2025Allow300YesNo
19032739MUSCLE TARGETING COMPLEXES AND USES THEREOF FOR TREATING DYSTROPHINOPATHIESJanuary 2025April 2025Allow300YesNo
18992944CONJUGATES OF PSMA-BINDING MOIETIES WITH CYTOTOXIC AGENTSJanuary 2025November 2025Allow1010YesNo
19006633BISPECIFIC CHIMERIC ANTIGEN RECEPTORS TARGETING CD20 AND BCMADecember 2024October 2025Allow1021YesNo
18989801Anti-PD-1 Antibodies and Fusion ProteinsDecember 2024November 2025Allow1011YesNo
18987178ANTI-CD161 ANTIBODIES AND USES THEREOFDecember 2024February 2025Allow200NoNo
18942051COMPOSITIONS AND METHODS FOR TREATMENT OF THYROID EYE DISEASENovember 2024January 2026Allow1540YesNo
18919094COMPOSITIONS AND METHODS RELATED TO TUMOR ACTIVATED ANTIBODIES TARGETING EGFR AND EFFECTOR CELL ANTIGENSOctober 2024July 2025Allow910NoNo
18919069ANTIGEN BINDING POLYPEPTIDESOctober 2024January 2025Allow300YesNo
18915927CHIMERIC ANTIGEN RECEPTORS AND RELATED METHODS AND COMPOSITIONS FOR THE TREATMENT OF CANCEROctober 2024July 2025Allow900YesNo
18911506MUSCLE TARGETING COMPLEXES AND USES THEREOF FOR TREATING DYSTROPHINOPATHIESOctober 2024January 2025Allow410NoNo
18907087BINDING AGENTS AND METHODS OF USING THE SAMEOctober 2024March 2025Allow510YesNo
18905034TL1A ASSOCIATED ANTIBODY COMPOSITIONS AND METHODS OF USEOctober 2024April 2025Allow601YesNo
18887598ANTIBODIES SPECIFICALLY BINDING TO CD147 AND USES THEREOFSeptember 2024March 2025Allow610YesNo
18826183FUSION PROTEINS FOR IMMUNOTHERAPY AGAINST CANCER AND INFECTIOUS DISEASESSeptember 2024June 2025Allow910NoNo
18821707IMMUNOCONJUGATES AND METHODSAugust 2024December 2024Allow410YesNo
18821730IMMUNOCONJUGATES AND METHODSAugust 2024December 2024Allow410YesNo
18821718IMMUNOCONJUGATES AND METHODSAugust 2024December 2024Allow410YesNo
18821737IMMUNOCONJUGATES AND METHODSAugust 2024December 2024Allow410YesNo
18821716OLIGOMERIC IgG FOR IMMUNOTHERAPEUTICS AND DIAGNOSTICSAugust 2024November 2025Allow1520NoNo
18807087DIMERIC ANTIBODIESAugust 2024May 2025Allow920NoNo
18807097METHODS OF MANUFACTURING DIMERIC ANTIBODIESAugust 2024February 2025Allow610NoNo
18805937MUSCLE TARGETING COMPLEXES AND USES THEREOF FOR TREATING DYSTROPHINOPATHIESAugust 2024December 2024Allow410NoNo
18805883MUSCLE TARGETING COMPLEXES AND USES THEREOF FOR TREATING DYSTROPHINOPATHIESAugust 2024December 2024Allow410NoNo
18793279ANTIBODIES TARGETING CCR2August 2024September 2024Allow200NoNo
18774123DOSING REGIMEN FOR TREATING INFLAMMATORY BOWEL DISEASEJuly 2024April 2025Allow911YesNo
18774143METHOD OF TREATING INFLAMMATORY BOWEL DISEASEJuly 2024September 2024Allow230YesNo
18755457ANTIBODIES BINDING TO FIBROBLAST ACTIVATION PROTEIN ALPHA AND DEATH RECEPTOR 4June 2024March 2025Allow910YesNo
18753928Albumin Bound Macromolecule Tri-Agonist Activating GLP 1/GIP/Glucagon Receptors And Methods ThereforJune 2024November 2025Allow1731YesNo
18734892TAU BINDING COMPOUNDSJune 2024February 2025Allow810NoNo
18674755TREATMENT OF NSCLC PATIENTS WITH TUMOR INFILTRATING LYMPHOCYTE THERAPIESMay 2024November 2025Allow1831YesNo
18657397ANTI-CD228 ANTIBODIES AND ANTIBODY-DRUG CONJUGATESMay 2024August 2025Abandon1510NoNo
18656234ANTIBODIES AND ANTIBODY-DRUG CONJUGATES TARGETING CLAUDIN 6May 2024August 2024Allow300NoNo
18654902POLYOXAZOLINE-DRUG CONJUGATES WITH NOVEL PHARMACOKINETIC PROPERTIESMay 2024April 2025Allow1120YesNo
18654735POLYOXAZOLINE-DRUG CONJUGATES WITH NOVEL PHARMACOKINETIC PROPERTIESMay 2024April 2025Allow1120YesNo
18643312BISPECIFIC OR-GATE CHIMERIC ANTIGEN RECEPTOR RESPONSIVE TO CD20 and CD19April 2024October 2024Allow621NoNo
18640982COMPOSITIONS TARGETING BCMA AND METHODS OF USE THEREOFApril 2024December 2024Allow800YesNo
18638136ANTIBODIES BINDING TO HLA-A2/MAGE-A4April 2024February 2026Abandon2210NoNo
18630058STING SENSITIZING AGENTSApril 2024April 2025Abandon1210NoNo
18626607CHIMERIC POLYPEPTIDE ASSEMBLY AND METHODS OF MAKING AND USING THE SAMEApril 2024July 2025Abandon1511NoNo
18623246BISPECIFIC OR-GATE CHIMERIC ANTIGEN RECEPTOR RESPONSIVE TO CD20 and CD19April 2024October 2024Allow720NoNo
18618626Bispecific Constructs for Target and Complement EngagementMarch 2024January 2025Allow1021YesNo
18695296ANTIBODY, ANTIBODY-DRUG CONJUGATE THEREOF AND USE THEREOFMarch 2024February 2026Allow2300YesNo
18612854CD19/CD38 MULTISPECIFIC ANTIBODIESMarch 2024September 2024Allow520YesNo
18611460ANTIBODIES WITH MUTATED HEAVY CHAIN CONSTANT REGIONSMarch 2024October 2025Allow1840YesNo
18611087HUMAN PD-L2 ANTIBODIES AND METHODS OF USE THEREFORMarch 2024May 2025Allow1410YesNo
18609032MUSCLE TARGETING COMPLEXES AND USES THEREOF FOR TREATING MYOTONIC DYSTROPHYMarch 2024July 2024Allow410YesNo
18602451ANTIBODY-EXATECAN CONJUGATESMarch 2024September 2025Abandon1821YesNo
18595279LINKERS, DRUG LINKERS AND CONJUGATES THEREOF AND METHODS OF USING THE SAMEMarch 2024April 2025Abandon1310NoNo
18595275LINKERS, DRUG LINKERS AND CONJUGATES THEREOF AND METHODS OF USING THE SAMEMarch 2024December 2024Abandon910NoNo
18590651CYTOTOXICITY-INDUCING THERAPEUTIC AGENTFebruary 2024November 2025Allow2140YesNo
18590865SIRP ALPHA, SIRP BETA 1, AND SIRP GAMMA ANTIBODIES AND USES THEREOFFebruary 2024August 2024Allow610YesNo
18588587USE OF ANTI-CD40 ANTIBODIES FOR TREATMENT OF INFLAMMATORY CONDITIONSFebruary 2024October 2025Abandon2010NoNo
18582950ANTI-CD161 ANTIBODIES AND USES THEREOFFebruary 2024September 2024Allow701YesNo
18432567METHOD OF MODIFYING ISOELECTRIC POINT OF ANTIBODY VIA AMINO ACID SUBSTITUTION IN CDRFebruary 2024August 2024Allow710NoNo
18429758CHIMERIC ANTIGEN RECEPTOR COMPOSITIONS AND METHODS FOR TREATING MUC1* DISEASESFebruary 2024August 2024Allow610NoNo
18430202ANTI-ROR1 ANTIBODY AND ROR1-TARGETING ENGINEERED CELLSFebruary 2024September 2025Allow2010NoNo
18425859METHOD OF MODIFYING ISOELECTRIC POINT OF ANTIBODY VIA AMINO ACID SUBSTITUTION IN CDRJanuary 2024August 2024Allow610YesNo
18408414PROTEINS THAT BIND SP17 INCLUDING FULLY-HUMAN ANTI-SP17 ANTIBODIESJanuary 2024February 2026Allow2540YesNo
18407065ANTI-L1CAM ANTIBODIES AND USES THEREOFJanuary 2024August 2025Allow1920NoNo
18575650ANTIGEN-BINDING POLYPEPTIDE TARGETING B7H3 AND APPLICATION THEREOFDecember 2023August 2024Allow810NoNo
18396418DIMERIC ANTIBODIESDecember 2023July 2024Allow710NoNo
18396466METHODS OF MANUFACTURING DIMERIC ANTIBODIESDecember 2023July 2024Allow710NoNo
18393322UNIVERSAL ANTI-CD22 CHIMERIC ANTIGEN RECEPTOR ENGINEERED IMMUNE CELLSDecember 2023July 2024Allow710NoNo
18392623ANTI-CD79B ANTIBODIES AND IMMUNOCONJUGATES AND METHODS OF USEDecember 2023July 2025Abandon1910NoNo
18518353COMPOSITIONS AND METHODS FOR TREATING HEMATOLOGICAL CANCERS TARGETING THE SIRPALPHA - CD47 INTERACTIONNovember 2023November 2025Abandon2420NoNo
18517345Use of Combination of Anti-PD-1 Antibody and VEGFR Inhibitor in Preparation of Drug for Treating CancersNovember 2023May 2025Allow1820YesNo
18511818CEACAM5 ANTIBODY-DRUG CONJUGATES AND METHODS OF USE THEREOFNovember 2023September 2024Abandon1010NoNo
18388036PD-1 Peptide InhibitorsNovember 2023March 2025Abandon1600NoNo
18503245PHARMACEUTICAL COMPOSITIONS COMPRISING ANTI-HUMAN TSLP RECEPTOR ANTIBODIES AND METHODS OF USING THE SAMENovember 2023July 2024Allow810NoNo
18559201COMPOSITIONS AND METHODS RELATED TO TUMOR ACTIVATED ANTIBODIES TARGETING EGFR AND EFFECTOR CELL ANTIGENSNovember 2023August 2024Allow910YesNo
18384508PD-ECGF AS BIOMARKER OF CANCEROctober 2023December 2024Allow1410YesNo
18495086MUSCLE TARGETING COMPLEXES AND USES THEREOF FOR TREATING FACIOSCAPULOHUMERAL MUSCULAR DYSTROPHYOctober 2023February 2024Allow310NoNo
18494007HER-2 TARGETED BISPECIFIC COMPOSITIONS AND METHODS FOR MAKING AND USING THE SAMEOctober 2023December 2024Allow1320NoNo
18493623BIPARATOPIC FR-ALPHA ANTIBODIES AND IMMUNOCONJUGATESOctober 2023August 2025Abandon2210NoNo
18492311CANCER THERAPYOctober 2023December 2024Abandon1410NoNo
18492141IMMUNOSTIMULATORY AGENTS IN COMBINATION WITH ANGIOGENESIS INHIBITORSOctober 2023April 2025Abandon1810NoNo
18383043ANTI-CEACAM6 ANTIBODIES AND METHODS OF USEOctober 2023October 2024Allow1110NoNo
18491182CANINE MONOCLONAL ANTIBODIES AGAINST CANINE CYTOTOXIC T LYMPHOCYTE ASSOCIATED PROTEIN 4 (CTLA-4)October 2023June 2024Allow710NoNo
18481547METHODS OF USING RARy AGONISTS FOR CANCER TREATMENTOctober 2023June 2024Allow800YesNo

Appeals Overview

This analysis examines appeal outcomes and the strategic value of filing appeals for art-unit 1643.

Patent Trial and Appeal Board (PTAB) Decisions

Total PTAB Decisions
117
Examiner Affirmed
77
(65.8%)
Examiner Reversed
40
(34.2%)
Reversal Percentile
58.5%
Higher than average

What This Means

With a 34.2% reversal rate, the PTAB reverses the examiner's rejections in a meaningful percentage of cases. This reversal rate is above the USPTO average, indicating that appeals have better success here than typical.

Strategic Value of Filing an Appeal

Total Appeal Filings
1130
Allowed After Appeal Filing
225
(19.9%)
Not Allowed After Appeal Filing
905
(80.1%)
Filing Benefit Percentile
6.9%
Lower than average

Understanding Appeal Filing Strategy

Filing a Notice of Appeal can sometimes lead to allowance even before the appeal is fully briefed or decided by the PTAB. This occurs when the examiner or their supervisor reconsiders the rejection during the mandatory appeal conference (MPEP § 1207.01) after the appeal is filed.

In this dataset, 19.9% of applications that filed an appeal were subsequently allowed. This appeal filing benefit rate is in the bottom 25% across the USPTO, indicating that filing appeals is less effective here than in most other areas.

Strategic Recommendations

✓ Appeals to PTAB show good success rates. If you have a strong case on the merits, consider fully prosecuting the appeal to a Board decision.

⚠ Filing a Notice of Appeal shows limited benefit. Consider other strategies like interviews or amendments before appealing.

Art Unit 1643 - Prosecution Statistics Summary

Executive Summary

Art Unit 1643 is part of Group 1640 in Technology Center 1600. This art unit has examined 11,241 patent applications in our dataset, with an overall allowance rate of 53.6%. Applications typically reach final disposition in approximately 36 months.

Comparative Analysis

Art Unit 1643's allowance rate of 53.6% places it in the 10% percentile among all USPTO art units. This art unit has a significantly lower allowance rate than most art units at the USPTO.

Prosecution Patterns

Applications in Art Unit 1643 receive an average of 1.96 office actions before reaching final disposition (in the 55% percentile). The median prosecution time is 36 months (in the 26% percentile).

Strategic Considerations

When prosecuting applications in this art unit, consider the following:

  • The art unit's allowance rate suggests a more challenging examination environment compared to the USPTO average.
  • With more office actions than average, plan for relatively streamlined prosecution.
  • The median prosecution time is longer than average and should be factored into your continuation and client communication strategies.
  • Review individual examiner statistics within this art unit to identify examiners with particularly favorable or challenging prosecution patterns.

Important Disclaimer

Not Legal Advice: The information provided in this report is for informational purposes only and does not constitute legal advice. You should consult with a qualified patent attorney or agent for advice specific to your situation.

No Guarantees: We do not provide any guarantees as to the accuracy, completeness, or timeliness of the statistics presented above. Patent prosecution statistics are derived from publicly available USPTO data and are subject to data quality limitations, processing errors, and changes in USPTO practices over time.

Limitation of Liability: Under no circumstances will IronCrow AI be liable for any outcome, decision, or action resulting from your reliance on the statistics, analysis, or recommendations presented in this report. Past prosecution patterns do not guarantee future results.

Use at Your Own Risk: While we strive to provide accurate and useful prosecution statistics, you should independently verify any information that is material to your prosecution strategy and use your professional judgment in all patent prosecution matters.